Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

New bio-equivalence rules promise safer drugs but could eliminate pharma manufacturers that make medicines affordable. Is there a middle gr...

In a statement, the Hyderabad-based company that reported Rs 15 crore of revenue last fiscal year, said it would soon take up clinical stud...

Torrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, a...

Modi’s latest salvo has resurrected the ghost for the Rs 17,000 crore Indian pharma market dominated by branded generics.

The inspection was conducted during June 29, 2015 to July 7, 2015 at the Taloja plant, it added.

Germany's drug regulator has suspended the marketing of 54 medicines clinically tested by India's GVK Biosciences in compliance.

Medicines affected by the sales ban will lose their validity for use in the EU and they should no longer be sold by pharmaceutical companie...

The US regulator has issued a warning letter to Sharon Bio-medicine for failing to pay generic drug user fee by its owner for three years.

Lupin said that company has successfully conducted the new bio equivalence (BE) studies for the said products and submitted the report to E...

The Federal Institute for Medicines and Medical Products, which issues the licences in Germany, confirmed it has been investigating the all...

Transgene Biotek has announced that Stream Value Fund has agreed to join hands on a long-term basis to support its drug discovery activity.

The US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promis...

US-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.

Jubilant Organosys is planning to expand its presence in the generic drugs space. The company plans to file applications to sell 10 off-pat...

A leading Malaysian drug and biotechnology firm will sign a USD two million deal with India's Avestha Gengraine Technologies Pvt Ltd to man...

At a time when the US generic drugs market is reeling under price competition, a recent move by the US government to accelerate approvals o...